应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
AZN 阿斯利康
休市中 07-18 16:00:00 EDT
68.79
-0.47
-0.68%
盘后
68.85
+0.06
+0.09%
19:51 EDT
最高
69.61
最低
68.67
成交量
299.22万
今开
69.59
昨收
69.26
日振幅
1.36%
总市值
2,133亿
流通市值
2,124亿
总股本
31.01亿
成交额
2.07亿
换手率
0.10%
流通股本
30.88亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
阿斯利康7月17日成交额为2.56亿美元
市场透视 · 07-18 01:19
阿斯利康7月17日成交额为2.56亿美元
30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易
创鉴汇 · 07-17
30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易
巨头加码,三抗成为“新风口”
药智网 · 07-17
巨头加码,三抗成为“新风口”
阿斯利康(AZN.US)罕见病药物试验未达预期,股价小幅下跌
智通财经 · 07-16
阿斯利康(AZN.US)罕见病药物试验未达预期,股价小幅下跌
上半年20起大型药企与中国创新药公司交易!
创鉴汇 · 07-16
上半年20起大型药企与中国创新药公司交易!
第十一批集采来了!440亿市场巨震,倍特、科伦发力,11个超10亿品种承压,3大注射剂遭围攻
米内网 · 07-16
第十一批集采来了!440亿市场巨震,倍特、科伦发力,11个超10亿品种承压,3大注射剂遭围攻
阿斯利康股价下跌1%
每日经济新闻 · 07-16
阿斯利康股价下跌1%
阿斯利康一款药物未能达到研究的主要目标
格隆汇 · 07-16
阿斯利康一款药物未能达到研究的主要目标
阿斯利康7月15日成交额为2.25亿美元
市场透视 · 07-16
阿斯利康7月15日成交额为2.25亿美元
万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系
金融界 · 07-15
万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系
中国生物制药拟5亿美元收购创新药企,后者曾与阿斯利康、默沙东达成授权交易
澎湃新闻 · 07-15
中国生物制药拟5亿美元收购创新药企,后者曾与阿斯利康、默沙东达成授权交易
杭州市市长姚高员会见阿斯利康全球执行副总裁尹思睿一行
E公司 · 07-14
杭州市市长姚高员会见阿斯利康全球执行副总裁尹思睿一行
阿斯利康重磅高血压新药 III 期成功
Insight数据库 · 07-14
阿斯利康重磅高血压新药 III 期成功
阿斯利康7月11日成交额为1.94亿美元
市场透视 · 07-12
阿斯利康7月11日成交额为1.94亿美元
阿斯利康7月10日成交额为2.91亿美元
市场透视 · 07-11
阿斯利康7月10日成交额为2.91亿美元
阿斯利康7月9日成交额为2.58亿美元
市场透视 · 07-10
阿斯利康7月9日成交额为2.58亿美元
10亿美元收购后,阿斯利康体内CAR-T疗法首战告捷
药事纵横 · 07-09
10亿美元收购后,阿斯利康体内CAR-T疗法首战告捷
阿斯利康7月8日成交额为2.86亿美元
市场透视 · 07-09
阿斯利康7月8日成交额为2.86亿美元
阿斯利康7月7日成交额为3.10亿美元
市场透视 · 07-08
阿斯利康7月7日成交额为3.10亿美元
近期交易合作|阿斯利康有意购入依沃西单抗,晶泰科技与辉瑞扩大合作
药菓 · 07-07
近期交易合作|阿斯利康有意购入依沃西单抗,晶泰科技与辉瑞扩大合作
加载更多
公司概况
公司名称:
阿斯利康
所属市场:
NASDAQ
上市日期:
--
主营业务:
阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。
发行价格:
--
{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":68.79,"timestamp":1752868800000,"preClose":69.26,"halted":0,"volume":2992178,"hourTrading":{"tag":"盘后","latestPrice":68.85,"preClose":68.79,"latestTime":"19:51 EDT","volume":53574,"amount":3685517.248,"timestamp":1752882671997},"delay":0,"floatShares":3088062322,"shares":3101341336,"eps":2.484749,"marketStatus":"休市中","change":-0.47,"latestTime":"07-18 16:00:00 EDT","open":69.59,"high":69.61,"low":68.665,"amount":206693881.33646,"amplitude":0.013644,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.484749,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":7,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NASDAQ","adjPreClose":69.26,"dividendRate":0.022532,"preHourTrading":{"tag":"盘前","latestPrice":69.55,"preClose":69.26,"latestTime":"09:29 EDT","volume":62127,"amount":4325401.02384,"timestamp":1752845399462},"postHourTrading":{"tag":"盘后","latestPrice":68.85,"preClose":68.79,"latestTime":"19:51 EDT","volume":53574,"amount":3685517.248,"timestamp":1752882671997},"volumeRatio":0.9024767741888104,"impliedVol":0.3123,"impliedVolPercentile":0.768},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2552583014","title":"阿斯利康7月17日成交额为2.56亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552583014","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552583014?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:19","pubTimestamp":1752801552,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日,阿斯利康成交额为2.56亿美元,成交额较昨日增加2.81%,当日成交量为369.87万股。阿斯利康于2025年7月17日跌1.17%,报69.26美元,该股过去5个交易日跌3.55%,年初至今涨7.43%,过去60日涨3.53%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-17|2.56亿|2.81%|369.87万|#|2025-07-16|2.49亿|10.48%|354.30万|#|2025-07-15|2.25亿|-7.72%|319.20万|#|2025-07-14|2.44亿|26.16%|340.19万|#|2025-07-11|1.94亿|-33.45%|272.99万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091922a6b0d50c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091922a6b0d50c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","LU0320765992.SGD","LU2456880835.USD","LU2236285917.USD","LU0889565916.HKD","BK4588","BK4007","LU1829250122.USD","LU2417539215.USD","BK4585","BK4568","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2552488142","title":"30起交易近138亿美元!默沙东达成100亿美元大额并购;艾伯维超19亿美元引进三抗管线 | 一周交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2552488142","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552488142?lang=zh_cn&edition=full","pubTime":"2025-07-17 17:23","pubTimestamp":1752744181,"startTime":"0","endTime":"0","summary":"据创鉴汇不完全统计,7月7日至7月13日全球生物制药领域共披露30起交易事件,潜在交易总额近138亿美元。上周最重磅的交易当属默沙东以100亿美元收购Verona Pharma,这也是2025年迄今创新药领域第二大并购。本次交易不仅巩固了默沙东在心肺疾病领域的产品管线,还进一步强化了其在慢性疾病治疗市场的竞争优势。上周CGT领域交易增多,涉及4起基因疗法技术合作,1起CAR-T领域并购及1起干细胞移植治疗的合作研发。上周中国公司达成多起跨国交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717173302a6af7815&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0203345920.USD","AZN","IE0009355771.USD","LU0320765489.SGD","LU1989771016.USD","SG9999001440.SGD","LU2236285917.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0265550359.USD","LU2361045086.USD","LU2023250504.SGD","SG9999002224.SGD","SG9999013999.USD","LU2468319806.SGD","LU0889565916.HKD","LU2361044865.SGD","IE00BLSP4452.SGD","LU1941712264.USD","LU1066051225.USD","02616","LU1066051811.HKD","SG9999015341.SGD","LU2324357040.USD","LU1934455277.USD","LU2112291526.USD","LU0965508806.USD","LU0058720904.USD","LU1829250122.USD","LU0266013472.USD","BK4007","LU0208291251.USD","MRK","LU1974910355.USD","LU0234572021.USD","LU1023059063.AUD","LU1699723380.USD","SG9999015358.SGD","LU0965509283.SGD","IE00BFTCPJ56.SGD","LU2461242641.AUD","LU0265550946.USD","LU1162221912.USD","LU2106854487.HKD","BK4585","LU1291159041.SGD","LU2023250843.SGD","LU2417539215.USD","SG9999014567.USD","IE00BN8TJ469.HKD","LU0238689110.USD"],"gpt_icon":0},{"id":"2552107687","title":"巨头加码,三抗成为“新风口”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552107687","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552107687?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:03","pubTimestamp":1752739384,"startTime":"0","endTime":"0","summary":"ISB 2001在组合中加入CD38,增强对BCMA低表达肿瘤细胞的结合能力,并通过下调抗原表达来阻止癌症产生耐药性,有望成为新一代治疗多发性骨髓瘤的药物。02三抗正在成为新风口单克隆抗体药物因其特异性强、靶向性高和毒副作用小等特点,已在肿瘤、自身性免疫疾病等领域广泛应用。目前,全球已有多款双特异性抗体药物获批上市,适应证主要集中在肿瘤领域。在国内药企中,三特异性抗体同样受到追崇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B19Z4B17.USD","IE00B7SZL793.SGD","JNJ","MRK","CR","BK4161","IE0031619046.USD","LU2065731478.USD","BK4006","CRS","BK4077","AZN","SLE","IE00B66KJ199.SGD","PFE","IGI","ORR"],"gpt_icon":0},{"id":"2551235871","title":"阿斯利康(AZN.US)罕见病药物试验未达预期,股价小幅下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2551235871","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551235871?lang=zh_cn&edition=full","pubTime":"2025-07-16 20:55","pubTimestamp":1752670517,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,阿斯利康在研药物安塞拉米单抗针对AL淀粉样变性的Ⅲ期临床试验未能达到延长患者生存期或减少心脏相关住院次数的主要终点,这一结果与此前业界对重症患者可能获益的期待形成落差。受试验结果影响,阿斯利康股价在盘前交易阶段下跌0.61%,报收69.89美元,总市值2180亿美元。阿斯利康表示,将持续推进安塞拉米单抗的数据分析,并探索其在更精准患者群体中的适用性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BK4585","BK4588","LU0109394709.USD","BK4568","LU2236285917.USD","LU2456880835.USD","AZN","LU0320765992.SGD","LU2462157665.USD","LU2417539215.USD","LU0889565916.HKD","LU1829250122.USD"],"gpt_icon":0},{"id":"2551141731","title":"上半年20起大型药企与中国创新药公司交易!","url":"https://stock-news.laohu8.com/highlight/detail?id=2551141731","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551141731?lang=zh_cn&edition=full","pubTime":"2025-07-16 17:08","pubTimestamp":1752656931,"startTime":"0","endTime":"0","summary":"2025年上半年,大型药企与中国创新药公司之间的交易活动活跃度提高,反映出中国在全球创新药领域的快速崛起和强大吸引力。根据创鉴汇不完全统计,上半年中国创新药企与大型药企共达成20笔交易,披露的交易潜在总金额近300亿美元,其中单笔最高达60.5亿美元,显示出大型药企对中国创新药的高度信心。协议包括首付款8000万美元,潜在交易总额20.1亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SG9999001176.USD","01530","ORR","BK4534","LU2417539215.USD","LU1066051498.USD","BK4588","LU2456880835.USD","LU0321505868.SGD","IE00B19Z3B42.SGD","03692","LU0868494617.USD","LU0306806265.USD","LU0109394709.USD","LU0225284248.USD","BK4550","LU0321505439.SGD","IE00BLSP4239.USD","IE00B19Z3581.USD","01093","BK4007","BK4581","LU0456855351.SGD","IE00BBT3K403.USD","LU0170899867.USD","AZN","BK4080","LU1883839398.USD","BK4599","BK4585","IE0002270589.USD","LU1894683348.USD","BK4592","SG9999002224.SGD","MRK","LU0306807586.USD","PFE","SG9999001176.SGD","SG9999011175.SGD","LU2462157665.USD","SG9999003800.SGD","SGXZ57979304.SGD","LU2236285917.USD","LU0889565916.HKD","ADC","LU0234572021.USD","LU0122379950.USD","LU1894683264.USD","SG9999002232.USD","IE000M9KFDE8.USD","MSD","LU0985481810.HKD","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2551145195","title":"第十一批集采来了!440亿市场巨震,倍特、科伦发力,11个超10亿品种承压,3大注射剂遭围攻","url":"https://stock-news.laohu8.com/highlight/detail?id=2551145195","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551145195?lang=zh_cn&edition=full","pubTime":"2025-07-16 16:08","pubTimestamp":1752653337,"startTime":"0","endTime":"0","summary":"精彩内容第十一批集采药品名单来了!近日,上海阳光医药采购网发布开展第十一批国采相关药品信息填报工作的通知,拟纳入55个品种。55个品种销售额均超过1亿元,其中超10亿大品种有11个,占比20%;超5亿元且不足10亿元的品种有17个,占比接近31%;超1亿元且不足5亿元的品种有27个,占比约49%。值得一提的是,第十一批国采将首次纳入化药贴膏剂。55个品种剂型分布情况10个品种遭“围攻”!","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716161940a44e3506&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716161940a44e3506&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","BK4588","BK4585","BK4007","LU0320765992.SGD","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","LU2462157665.USD","02196","BK4568","LU2417539215.USD","LU1829250122.USD","LU2236285917.USD","01093","600196"],"gpt_icon":0},{"id":"2551148722","title":"阿斯利康股价下跌1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551148722","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551148722?lang=zh_cn&edition=full","pubTime":"2025-07-16 15:26","pubTimestamp":1752650806,"startTime":"0","endTime":"0","summary":"阿斯利康股价下跌1%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507163458746086.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507163458746086.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2456880835.USD","BK4568","AZN","BK4588","LU2462157665.USD","LU0320765992.SGD","LU2417539215.USD","BK4585","LU2236285917.USD","LU0889565916.HKD","LU1829250122.USD","BK4007","LU0109394709.USD"],"gpt_icon":0},{"id":"2551117486","title":"阿斯利康一款药物未能达到研究的主要目标","url":"https://stock-news.laohu8.com/highlight/detail?id=2551117486","media":"格隆汇","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551117486?lang=zh_cn&edition=full","pubTime":"2025-07-16 14:17","pubTimestamp":1752646664,"startTime":"0","endTime":"0","summary":"格隆汇7月16日|阿斯利康周三表示,其实验性药物Anselamimab没有达到治疗AL淀粉样变性疾病的晚期研究的主要目标。AL淀粉样变性是一种罕见的疾病,会导致体内蛋白质沉积增多,造成重大器官损伤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071614180997a80e12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071614180997a80e12&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","BK4588","BK4585","BK4007","LU0320765992.SGD","LU0889565916.HKD","LU2456880835.USD","LU0109394709.USD","LU2462157665.USD","BK4568","LU2417539215.USD","LU1829250122.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2551151971","title":"阿斯利康7月15日成交额为2.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551151971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551151971?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:19","pubTimestamp":1752628792,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日,阿斯利康成交额为2.25亿美元,成交额较昨日减少7.72%,当日成交量为319.20万股。阿斯利康于2025年7月15日跌1.98%,报70.32美元,该股过去5个交易日涨0.43%,年初至今涨9.07%,过去60日涨4.88%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-15|2.25亿|-7.72%|319.20万|#|2025-07-14|2.44亿|26.16%|340.19万|#|2025-07-11|1.94亿|-33.45%|272.99万|#|2025-07-10|2.91亿|12.57%|404.67万|#|2025-07-09|2.58亿|-9.53%|366.55万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091955a6ac2e02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091955a6ac2e02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0320765992.SGD","LU2236285917.USD","BK4568","LU2417539215.USD","AZN","BK4585","BK4588","LU1829250122.USD","LU0889565916.HKD","LU2462157665.USD","LU2456880835.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2551917381","title":"万邦医药股价下跌1.95% 公司澄清与辉瑞、阿斯利康无合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2551917381","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551917381?lang=zh_cn&edition=full","pubTime":"2025-07-16 02:30","pubTimestamp":1752604208,"startTime":"0","endTime":"0","summary":"万邦医药股价报45.31元,较前一交易日下跌0.90元。当日开盘价为45.71元,最高触及45.90元,最低下探44.35元,成交量为23988手,成交金额达1.08亿元。万邦医药属于医疗服务板块,公司专注于医药研发领域。公开资料显示,该公司总市值为30.21亿元,流通市值为10.16亿元。公司方面消息显示,万邦医药在投资者互动平台明确表示,目前与辉瑞、阿斯利康等国际制药巨头均无合作关系。该表态是针对投资者关于公司业务合作情况的询问作出的回应。资金流向数据显示,万邦医药当日主力资金净流出964.66万元。风险提示:股市有风险,投资需谨慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/16023051721498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0122379950.USD","BK4599","SG9999001176.USD","SG9999013999.USD","LU2417539215.USD","IE00BLSP4452.SGD","BK4592","LU0321505439.SGD","LU0109394709.USD","LU1066053197.SGD","BK4585","LU0234572021.USD","BK0216","BK4533","LU2236285917.USD","LU1883839398.USD","SG9999011175.SGD","LU0306806265.USD","LU0456855351.SGD","LU0289739699.SGD","LU0889565916.HKD","SGXZ57979304.SGD","SG9999002224.SGD","BK4534","SG9999001176.SGD","LU0320765992.SGD","LU0170899867.USD","LU0985481810.HKD","LU1023059063.AUD","LU2456880835.USD","LU1894683348.USD","IE00B19Z3581.USD","IE00BBT3K403.USD","LU1057294990.SGD","LU0225771236.USD","LU2462157665.USD","SG9999002232.USD","301520","LU1829250122.USD","AZN","IE00BLSP4239.USD","BK4007","BK4588","IE000M9KFDE8.USD","BK4568","IE0002270589.USD","LU0225284248.USD","LU1894683264.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2551160578","title":"中国生物制药拟5亿美元收购创新药企,后者曾与阿斯利康、默沙东达成授权交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2551160578","media":"澎湃新闻","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551160578?lang=zh_cn&edition=full","pubTime":"2025-07-15 21:20","pubTimestamp":1752585642,"startTime":"0","endTime":"0","summary":"7月15日晚间,中国生物制药公告,将以约5亿美元的总价收购上海礼新医药95.09%股权,加上此前参与礼新C轮融资时既已取得的4.91%股权,交易完成后,礼新医药将成为中国生物制药全资子公司。礼新医药于2019年成立于上海,因先后与阿斯利康、默沙东等跨国药企达成BD交易而受到行业关注。当地时间6月11日,中国生物制药相关负责人曾对外表示,今年以来,对外授权交易已经成为公司重要战略目标之一,目前多项资产具备对外授权潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071521215397a717e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071521215397a717e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1585245621.USD","LU2417539215.USD","SG9999001440.SGD","BK4007","LU0965508806.USD","LU1989771016.USD","LU1989772840.SGD","LU1699723380.USD","SG9999015358.SGD","LU1023059063.AUD","LU0289739699.SGD","BK4588","AZN","LU2112291526.USD","LU1066051498.USD","SGXZ57979304.SGD","LU0208291251.USD","LU0238689110.USD","SG9999001176.USD","LU0265550946.USD","LU1093756325.SGD","LU0058720904.USD","BK4534","BK4533","LU2456880835.USD","MRK","SG9999014567.USD","LU1162221912.USD","LU1066053197.SGD","LU0234572021.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU1917777945.USD","IE00BJJMRZ35.SGD","LU2023250843.SGD","IE000M9KFDE8.USD","LU0965509010.AUD","LU1983299246.USD","IE00BBT3K403.USD","LU1934455277.USD","LU0109394709.USD","LU1430594728.SGD","LU1037948541.HKD","SG9999014575.USD","LU0098860793.USD","LU1093756168.USD","LU2089984988.USD","LU1061106388.HKD","SG9999014542.SGD"],"gpt_icon":0},{"id":"2551186639","title":"杭州市市长姚高员会见阿斯利康全球执行副总裁尹思睿一行","url":"https://stock-news.laohu8.com/highlight/detail?id=2551186639","media":"E公司","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551186639?lang=zh_cn&edition=full","pubTime":"2025-07-14 20:02","pubTimestamp":1752494568,"startTime":"0","endTime":"0","summary":"人民财讯7月14日电,据杭州发布,今天,杭州市市长姚高员会见阿斯利康全球执行副总裁、国际业务负责人尹思睿一行。姚高员说,希望阿斯利康继续深耕杭州,进一步加大投资布局,更好与本地创新药企开展深入合作,研发、生产、供给更多高质量的医药健康产品。我们将持续营造一流营商环境,为企业在杭发展提供优质服务,实现双方互利共赢。尹思睿表示,阿斯利康对进一步与杭州深化合作充满信心,将持续加大企业创新投入,不断拓展在杭业务布局,推动更多优质项目落地见效,更好服务医疗健康事业发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071420024897a5a4dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071420024897a5a4dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4585","LU0889565916.HKD","LU0109394709.USD","LU1829250122.USD","BK4588","BK4007","AZN","LU2236285917.USD","LU2417539215.USD","LU2462157665.USD","LU0320765992.SGD","LU2456880835.USD"],"gpt_icon":0},{"id":"2551723469","title":"阿斯利康重磅高血压新药 III 期成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2551723469","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551723469?lang=zh_cn&edition=full","pubTime":"2025-07-14 14:32","pubTimestamp":1752474726,"startTime":"0","endTime":"0","summary":"7 月 14 日,阿斯利康宣布,Baxdrostat 在针对未控制或难治性高血压患者的BaxHTN III 期临床试验中,达到了主要终点和所有次要终点。2023 年 2 月,阿斯利康 18 亿美元收购CinCor,囊获了该产品。目前,Baxdrostat 正在开展高血压、心力衰竭等多个适应症的临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714143828a44921de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0320765992.SGD","LU2417539215.USD","BK4134","LU0889565916.HKD","III","AZN","BK4007","LU1829250122.USD","LU2236285917.USD","BK4588","BK4568","LU2462157665.USD","LU2456880835.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2550131998","title":"阿斯利康7月11日成交额为1.94亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550131998","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550131998?lang=zh_cn&edition=full","pubTime":"2025-07-12 09:19","pubTimestamp":1752283190,"startTime":"0","endTime":"0","summary":"美东时间2025年7月11日,阿斯利康成交额为1.94亿美元,成交额较昨日减少33.45%,当日成交量为272.99万股。阿斯利康于2025年7月11日跌0.95%,报71.13美元,该股过去5个交易日涨2.42%,年初至今涨10.33%,过去60日涨4.59%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-11|1.94亿|-33.45%|272.99万|#|2025-07-10|2.91亿|12.57%|404.67万|#|2025-07-09|2.58亿|-9.53%|366.55万|#|2025-07-08|2.86亿|-7.75%|407.97万|#|2025-07-07|3.10亿|-34.41%|444.17万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091954a6a4bfcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091954a6a4bfcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2456880835.USD","LU0889565916.HKD","AZN","LU0109394709.USD","LU2236285917.USD","LU2462157665.USD","BK4585","LU2417539215.USD","BK4588","LU1829250122.USD","BK4568","LU0320765992.SGD","BK4007"],"gpt_icon":0},{"id":"2550679609","title":"阿斯利康7月10日成交额为2.91亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550679609","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550679609?lang=zh_cn&edition=full","pubTime":"2025-07-11 09:19","pubTimestamp":1752196789,"startTime":"0","endTime":"0","summary":"美东时间2025年7月10日,阿斯利康成交额为2.91亿美元,成交额较昨日增加12.57%,当日成交量为404.67万股。阿斯利康于2025年7月10日涨1.4%,报71.81美元,该股过去5个交易日涨0.96%,年初至今涨11.39%,过去60日涨8.33%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-10|2.91亿|12.57%|404.67万|#|2025-07-09|2.58亿|-9.53%|366.55万|#|2025-07-08|2.86亿|-7.75%|407.97万|#|2025-07-07|3.10亿|-34.41%|444.17万|#|2025-07-03|4.72亿|80.88%|676.80万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711091953a6a2908c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711091953a6a2908c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU2462157665.USD","AZN","LU0320765992.SGD","LU2417539215.USD","LU1829250122.USD","BK4007","BK4588","LU2236285917.USD","BK4568","BK4585","LU0109394709.USD","LU2456880835.USD"],"gpt_icon":0},{"id":"2550667104","title":"阿斯利康7月9日成交额为2.58亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550667104","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550667104?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:19","pubTimestamp":1752110350,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日,阿斯利康成交额为2.58亿美元,成交额较昨日减少9.53%,当日成交量为366.55万股。阿斯利康于2025年7月9日涨1.14%,报70.82美元,该股过去5个交易日跌0.9%,年初至今涨9.85%,过去60日涨9.17%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-09|2.58亿|-9.53%|366.55万|#|2025-07-08|2.86亿|-7.75%|407.97万|#|2025-07-07|3.10亿|-34.41%|444.17万|#|2025-07-03|4.72亿|80.88%|676.80万|#|2025-07-02|2.61亿|-45.64%|367.62万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091917a6a065a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091917a6a065a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0889565916.HKD","LU2462157665.USD","BK4588","BK4585","LU0320765992.SGD","LU2456880835.USD","LU0109394709.USD","AZN","LU2417539215.USD","LU2236285917.USD","LU1829250122.USD","BK4007","BK4568"],"gpt_icon":0},{"id":"2550687533","title":"10亿美元收购后,阿斯利康体内CAR-T疗法首战告捷","url":"https://stock-news.laohu8.com/highlight/detail?id=2550687533","media":"药事纵横","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550687533?lang=zh_cn&edition=full","pubTime":"2025-07-09 17:00","pubTimestamp":1752051600,"startTime":"0","endTime":"0","summary":"阿斯利康以最高10亿美元收购比利时生物技术公司EsoBiotec仅一个月后,7月7日,其核心资产在研体内CAR-T疗法ESO-T01便在《柳叶刀》披露首组临床数据,为这家传统药企的细胞基因治疗布局注入强心剂。此次收购是阿斯利康深化细胞基因治疗布局的关键一步。随着首个临床数据的公布,这款颠覆性体内CAR-T疗法的后续开发进程,将成为检验传统药企转型创新生物技术领域成效的重要标尺。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170435a43ff7ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2462157665.USD","LU0109394709.USD","BK4022","LU2417539215.USD","BK4007","CAR","BK4568","BK4588","BK4585","AZN","LU0889565916.HKD","LU2236285917.USD","LU2456880835.USD","BK4230","LU0320765992.SGD"],"gpt_icon":0},{"id":"2550577463","title":"阿斯利康7月8日成交额为2.86亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550577463","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550577463?lang=zh_cn&edition=full","pubTime":"2025-07-09 09:19","pubTimestamp":1752023943,"startTime":"0","endTime":"0","summary":"美东时间2025年7月8日,阿斯利康成交额为2.86亿美元,成交额较昨日减少7.75%,当日成交量为407.97万股。阿斯利康于2025年7月8日涨0.56%,报70.02美元,该股过去5个交易日涨0.2%,年初至今涨8.61%,过去60日涨4.88%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-08|2.86亿|-7.75%|407.97万|#|2025-07-07|3.10亿|-34.41%|444.17万|#|2025-07-03|4.72亿|80.88%|676.80万|#|2025-07-02|2.61亿|-45.64%|367.62万|#|2025-07-01|4.80亿|85.92%|673.11万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709091915a69e2134&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709091915a69e2134&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU0889565916.HKD","LU2462157665.USD","BK4588","BK4007","AZN","LU2417539215.USD","LU0320765992.SGD","LU0109394709.USD","LU2456880835.USD","LU2236285917.USD","BK4568","BK4585"],"gpt_icon":0},{"id":"2549567584","title":"阿斯利康7月7日成交额为3.10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549567584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549567584?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:18","pubTimestamp":1751937528,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日,阿斯利康成交额为3.10亿美元,成交额较昨日减少34.41%,当日成交量为444.17万股。阿斯利康于2025年7月7日涨0.26%,报69.63美元,该股过去5个交易日跌0.31%,年初至今涨8.0%,过去60日涨7.29%。|近5个交易日成交情况||||#|日期|成交额(美元)|成交额较昨日变化|成交量(股)|#|2025-07-07|3.10亿|-34.41%|444.17万|#|2025-07-03|4.72亿|80.88%|676.80万|#|2025-07-02|2.61亿|-45.64%|367.62万|#|2025-07-01|4.80亿|85.92%|673.11万|#|2025-06-30|2.58亿|17.66%|370.17万|1999年,瑞典的Astra和英国的Zeneca集团合并成立了阿斯利康。大部分销售额来自国际市场,其中美国占其销售额的近三分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091851a43ccc09&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091851a43ccc09&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","BK4585","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4007","LU2456880835.USD","LU2462157665.USD","AZN","BK4568","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2549736539","title":"近期交易合作|阿斯利康有意购入依沃西单抗,晶泰科技与辉瑞扩大合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2549736539","media":"药菓","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549736539?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:01","pubTimestamp":1751882490,"startTime":"0","endTime":"0","summary":"02晶泰科技与辉瑞深化战略合作6月30日,晶泰科技宣布与辉瑞扩大战略合作,共同开发全新一代的分子模拟平台以驱动新药研发。07腾盛博药与健康元签署抗菌新药许可协议7月4日,腾盛博药宣布已与健康元集团签署知识产权许可及技术转移协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191358a43bbb23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AZN","LU1023059063.AUD","BK4599","BK4533","IE000M9KFDE8.USD","SG9999002232.USD","LU0058720904.USD","BK4534","LU1894683348.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU2236285917.USD","LU0320765992.SGD","SG9999013999.USD","LU0289739699.SGD","LU0456855351.SGD","IE0002270589.USD","LU0306806265.USD","LU0234572021.USD","SG9999002224.SGD","LU0225284248.USD","SG9999001176.USD","SG9999001176.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU2417539215.USD","LU0170899867.USD","BK4568","LU0889565916.HKD","LU0985481810.HKD","LU1057294990.SGD","LU1829250122.USD","LU0868494617.USD","BK4581","BK4585","BK4592","IE00BLSP4239.USD","LU1066053197.SGD","LU0225771236.USD","LU0109394709.USD","PFE","LU1894683264.USD","SG9999011175.SGD","BK4007","LU0321505868.SGD","IE00BLSP4452.SGD","LU0306807586.USD","LU0122379950.USD","BK4550","LU2462157665.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0329},{"period":"1month","weight":-0.0278},{"period":"3month","weight":0.0178},{"period":"6month","weight":0.0329},{"period":"1year","weight":-0.1188},{"period":"ytd","weight":0.0499}],"compareEarnings":[{"period":"1week","weight":0.0064},{"period":"1month","weight":0.0504},{"period":"3month","weight":0.1922},{"period":"6month","weight":0.0502},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.0708}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年,公司出售了特种化学品业务。同样在1999年,该公司与瑞典Astra公司合并。2000年,该公司将农化业务分拆,并将其与诺华公司的同类业务合并,成立了一家新的公司Syngenta AG。2007年,集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年,集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.001428},{"month":2,"riseRate":0.40625,"avgChangeRate":-0.017129},{"month":3,"riseRate":0.5625,"avgChangeRate":0.027992},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018335},{"month":7,"riseRate":0.575758,"avgChangeRate":-0.004378},{"month":8,"riseRate":0.46875,"avgChangeRate":0.002026},{"month":9,"riseRate":0.5625,"avgChangeRate":0.002514},{"month":10,"riseRate":0.53125,"avgChangeRate":0.013465},{"month":11,"riseRate":0.5,"avgChangeRate":-0.000033},{"month":12,"riseRate":0.5625,"avgChangeRate":0.007964}],"exchange":"NASDAQ","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}